Medytox Reports Q1 Sales of 64 Billion KRW, Up 17% Year-on-Year

Record-High First-Quarter Sales
Driven by Balanced Growth in Domestic and Overseas Markets

On May 12, Medytox announced its first-quarter consolidated results, reporting sales of 64 billion KRW, operating profit of 5.5 billion KRW, and net profit of 3.3 billion KRW. Compared to the same period last year, sales grew by 17%, and both operating profit and net profit turned positive.

This record-high first-quarter performance was driven by balanced growth, with domestic sales increasing by 26% and overseas sales by 12% year-on-year. In particular, the Americas, including Brazil, posted remarkable growth of 88%, establishing themselves as key export markets.

By product category, sales of Medytox’s botulinum toxin products?including Meditoxin, Innotox, Coretox, and the newly added Newlux?achieved strong results, with domestic sales up 79% and overseas sales up 16% compared to the same period last year, thanks to the company’s differentiated four-product lineup.

Medytox expects the pace of sales growth to accelerate as Osong Plant 3 expands production and has begun full-scale overseas shipments since the second half of last year, especially as Newlux continues to gain overseas approvals.

A Medytox representative stated, "Medytox’s unique strength of having a diverse toxin portfolio has created synergy with brand awareness efforts, resulting in the highest first-quarter sales in our history. In the second quarter, we expect to continue obtaining overseas approvals for Newlux, and with the launch of two new lines of the hyaluronic acid filler Neuramis, we anticipate sustained sales growth going forward."

This content was produced with the assistance of AI translation services.